Blurred Vision on Ozempic or Mounjaro: Causes, How Long It Lasts, When It's Urgent

Blurred vision on Ozempic, Mounjaro or another GLP‑1 usually goes away when it comes from blood sugar falling fast in someone with diabetes, which temporarily changes how the lens focuses; no study has yet measured how often that is the cause in GLP‑1 users. In eye studies of people whose high glucose was brought down quickly, the blur peaked around ten days in and focus returned to normal within two to twelve weeks.^[5][6] Blur from worsening diabetic retinopathy does not clear on its own, and sudden loss of sight in one eye can be NAION, which usually does not recover. No US label lists blurred vision as a side effect of the drug itself; each mentions it only among the warning signs of a glucose low.^[1][4] The cause sets the outlook, and the pattern of the blur usually points to the cause.

Five causes, five outlooks

What the labels actually list

“Blurred vision” appears exactly once in each of the four current labels, and always in the same spot.^[1][2] The patient Medication Guide places it among the symptoms of hypoglycemia, beside dizziness, sweating, shakiness and slurred speech.^[3][4] It is not in the adverse-reaction tables of Ozempic, Wegovy, Mounjaro or Zepbound. That means no trial counted blur often enough on the drug, compared with placebo, for it to be listed as a side effect in its own right.

What the labels do carry is an instruction about vision change, filed under diabetic retinopathy.

Inform patients to contact their physician if changes in vision are experienced during treatment with OZEMPIC.

— Ozempic (semaglutide) prescribing information, section 17

Mounjaro carries the same instruction.^[3] The Wegovy and Zepbound versions are addressed to patients with type 2 diabetes.^[2][4] None of the four labels mentions NAION.

Cause one: the lens catching up with lower blood sugar

When blood sugar has been high for a while, glucose builds up in the lens of the eye and changes how strongly it bends light. Bring the sugar down quickly and the lens takes days to weeks to rebalance. During that window most people become temporarily more farsighted: distance may sharpen while reading blurs, or a prescription that fit last month suddenly does not.

The clearest measurements come from a Japanese study that tracked 28 eyes from the first day of intensive treatment for severe high blood sugar. Every patient developed the farsighted shift. It began on average 3.4 days after treatment started and peaked at 10.3 days, at an average of 1.47 diopters and as much as 3.75. Focus returned to its previous setting between 14 and 84 days. The faster glucose fell in the first week, the bigger the shift.^[5] The shape of the eye did not change; the authors placed the effect in the lens.^[5]

The Chinese study found the same thing in newly diagnosed patients, with focus restored two to four weeks after insulin was started, and the size of the shift tracked the starting HbA1c closely.^[6] Two smaller studies show it does not happen to everyone: a third of patients shifted in one,^[7] half in another, and two people became slightly more nearsighted instead.^[8] That last study also flagged the corneal changes during correction as a source of error for laser eye surgery and cataract measurements taken in the same period.^[8]

None of these studies involved a GLP‑1 drug, and none has measured refraction in people starting Ozempic or Mounjaro. Applying them here is inference, but it rests on the mechanism rather than the drug: what moves the lens is the fall in glucose, whatever causes it. Two things follow. Someone without diabetes, whose blood sugar was normal to begin with, has little glucose to correct, so this route explains far less blur in people taking Wegovy or Zepbound for weight alone. And someone with diabetes whose sugar was high at the start, and who drops quickly, is exactly the person the studies describe. A glasses prescription measured during the shift may not fit a few weeks later; ask the eye doctor whether to wait until glucose has settled.

Cause two: retinopathy getting worse early

The same rapid fall in glucose has a second, more serious effect in people who already have diabetic retinopathy: it can make the retinal disease temporarily worse. In SUSTAIN‑6, the two-year semaglutide heart trial in 3,297 people with type 2 diabetes, retinopathy complications ran higher on the drug, at a hazard ratio of 1.76.^[9] The Ozempic label puts it at 3.0% against 1.8% overall, 8.2% against 5.2% in people with retinopathy at the start, and 0.7% against 0.4% in those without.^[1] A follow-up analysis found that most of the excess may be attributed to how far and how fast HbA1c dropped in the first 16 weeks, in patients with existing retinopathy, poor control and insulin use.^[10] The Mounjaro and Zepbound labels, revised in August 2026, state that temporary worsening has been reported with rapid improvement in glucose control and ask for monitoring of anyone with a retinopathy history.^[3][4] One large records study found fewer retinal complications on tirzepatide than on other GLP‑1 drugs, a comparison its authors said needs prospective confirmation.^[11]

Early retinopathy has no symptoms. Later it causes blurry vision, floating spots and, untreated, blindness; swelling at the center of the retina is what blurs sight.^[12] Unlike the lens shift, this blur does not fade by waiting. It needs a dilated eye exam and, sometimes, injections or laser. Labels, trial numbers and the open questions are set out in GLP-1 eye risks: NAION and retinopathy.

Cause three: NAION, which is not blur

NAION, short for non-arteritic anterior ischemic optic neuropathy, is a failure of blood supply to the front of the optic nerve. It announces itself as a sudden, painless drop in sight in one eye, not as a gradual haze in both. Europe’s drug regulator reviewed semaglutide and NAION in June 2025 and placed it in the “very rare” frequency band, meaning at most one person in 10,000. The epidemiology it relied on came to about one additional case for every 10,000 years of patient treatment.^[13] Its instruction was direct: sudden loss of vision or rapidly worsening eyesight means contacting a doctor without delay, and semaglutide is stopped if NAION is confirmed.^[13] As of October 2026, the word appears in none of the US labels: not Ozempic,^[1] Wegovy,^[2] Mounjaro^[3] or Zepbound.^[4] The studies behind the European decision, and why they disagree, are on the NAION and retinopathy page.

Cause four: low blood sugar and low blood pressure

Low blood sugar is the one cause every label names, and it is the one that clears fastest. The Ozempic and Mounjaro labels tie the risk to taking the drug with insulin or a sulfonylurea such as glipizide.^[1][3] In Zepbound’s trial in people with type 2 diabetes, readings below 54 mg/dL occurred in 4.2% on the drug against 1.3% on placebo, and in 10.3% of those also taking a sulfonylurea against 2.1% of those who were not. The same label notes low blood sugar has also been linked to these drugs in adults without diabetes.^[4] Blur from a low comes with company: shakiness, sweating, hunger, a fast heartbeat, confusion.^[2] The NIH’s diabetes institute advises 15 to 20 grams of fast carbohydrate for a reading under 70 mg/dL, then a recheck after 15 minutes.^[14] Who is at risk, and what the label asks prescribers to change, is covered in GLP-1 low blood sugar risk.

Low blood pressure can blur or dim vision too. The NIH’s heart institute lists blurry vision among its symptoms and dehydration among its causes, and notes that sitting down may relieve them.^[15] On a GLP‑1, the setup is familiar: less food and fluid, vomiting or diarrhea during dose increases, weight loss lowering blood pressure, and blood pressure pills that were dosed for a heavier body. Blur that comes on when standing and passes within a minute fits this pattern. See dizziness on a GLP-1 and blood pressure pills and thirst and urination on a GLP-1.

Headache with vision change

Idiopathic intracranial hypertension, raised fluid pressure around the brain, presses on the optic nerve and can cause headaches, double vision, blind spots and brief episodes of blindness. It is most common in women aged 20 to 50, and obesity makes it more likely.^[16] That population overlaps heavily with people prescribed these drugs. It is not a known GLP‑1 side effect; the drugs are being studied as a possible treatment for it. Headache plus visual change belongs with a clinician the same day. The trial evidence is on GLP-1 headaches and intracranial pressure.

What the adverse-event databases show

Reports to the FDA’s adverse-event database add a signal, not a rate. A scan of reports from 2004 to 2024 found 119 drugs reported with visual blurring more often than expected; semaglutide was among them, with a reporting odds ratio of 3.26.^[17] A second analysis found eye complaints made up 3.61% of all GLP‑1 reports, with “vision blurred” the second most frequent after visual impairment. Its authors called the findings hypothesis-generating rather than causal, since the database has no count of how many people took each drug.^[18] Spontaneous reports also cannot separate blur caused by the drug from blur caused by the glucose change the drug is meant to produce.

When blurry vision is urgent

These patterns are not side effects to wait out. Each source below says to get care immediately.

• Sudden loss of vision, or eyesight worsening fast, in one eye. This is the NAION warning in Europe, and it fits other eye emergencies too.^[13]
• A shadow or “curtain” across part of the view, a burst of new floaters, or flashes of light. These are the signs of retinal detachment; the National Eye Institute says go to an eye doctor or emergency room right away.^[19]
• Intense eye pain with a red eye, blurry vision and nausea. This is how acute angle-closure glaucoma presents, a medical emergency.^[20] Nausea is also among the most common GLP‑1 side effects, which makes it easy to dismiss. Eye pain is not a GLP‑1 symptom.
• Sudden trouble seeing with a drooping face, arm weakness, slurred speech or a sudden severe headache. These are stroke signs; call 911.^[21] Slurred speech and confusion can also be a severe low, so check glucose if you can, but do not delay the call.
• New headache with double vision, blind spots or greying-out. Same-day care, for the reasons above.^[16]

If the blur is gradual and in both eyes

1. Tell the prescriber. The Ozempic and Mounjaro labels ask for this whenever vision changes,^[1][3] and the Wegovy and Zepbound labels ask it of people with type 2 diabetes.^[2][4] Do not stop or skip doses on your own; that decision belongs to the person managing your diabetes or weight.
2. Note the pattern. Both eyes or one; near or far; constant or coming and going; any link to standing up, skipped meals or the day of the injection. That narrows the cause quickly.
3. Get a dilated eye exam if you have diabetes. It is the only way to tell a lens shift from retinopathy. Ideally the exam happens before starting, so there is a baseline; if you already have retinopathy, ask who will check your eyes, and how often, while glucose comes down.
4. Hold off on new glasses if glucose is still falling. The refraction studies saw focus drift for up to twelve weeks.^[5] Ask the eye doctor whether a temporary pair or a wait makes more sense.
5. Ask about the pace. The retinopathy and refraction findings both point to the speed of the glucose drop.^[5][10] Whether that pace is something to manage is a fair question for the prescriber.